Lung Cancer
Show Only Open Trials
1.
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
- Study Status: Open to Enrollment
- Sponsor: Eastern Cooperative Oncology Group
2.
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy
- Study Status: Open to Enrollment
- Sponsor: Lilly
- Disease Status and/or Stage: Stage IV Non-Small Cell Lung Cancer
3.
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
- Study Status: Open to Enrollment
- Sponsor: Tragara Pharmaceuticals
- Disease Status and/or Stage: Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer
4.
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)
- Study Status: Open to Enrollment
- Sponsor: Eli Lily & Co.
- Disease Status and/or Stage: Unresectable, Locally Advance, Stage III Non-Small Cell Lung Cancer
5.
CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2cm) Peripheral Non-Small Cell Lung Cancer
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B, National Cancer Institute
- Disease Status and/or Stage: Non-small Cell Lung Cancer
6.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Open to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
7.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
8.
A Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in Patients with Malignances Known to Express NY-ESO-1
- Study Status: Closed to Enrollment
- Sponsor: Celldex Therapeutics
- Disease Status and/or Stage: Progressive Disease after therapies with curative potential or approved salvage regimen
9.
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism (VTE) in Patients with Cancer
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Any Stage of Cancer
